L-Tryptophan-kynurenine pathway enzymes are therapeutic target for neuropsychiatric diseases: Focus on cell type differences

Neuropharmacology

Volumn 112, Issue , 2017, Pages 264-274

  Fujigaki, Hidetsugu ^a   Yamamoto, Yasuko ^b   Saito, Kuniaki ^b,c  

^a HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Indoleamine 2,3 dioxygenase; Kynurenic acid; Kynurenine; Kynurenine 3 monooxygenase; Kynurenine aminotransferase; Kynurenine pathway; Quinolinic acid

Indexed keywords

3 HYDROXYKYNURENINE; AMINOTRANSFERASE INHIBITOR; INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INDOLEAMINE 2,3 DIOXYGENASE 2; JM 6; KYNURENIC ACID; KYNURENINE; KYNURENINE 3 MONOOXYGENASE; KYNURENINE AMINOTRANSFERASE; OXYGENASE INHIBITOR; PF 04859989; QUINOLINIC ACID; RECOMBINANT ALPHA INTERFERON; TRYPTOPHAN; TRYPTOPHAN 2,3 DIOXYGENASE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMINO ACID METABOLISM; ASTROCYTE; BLOOD BRAIN BARRIER; CELL SPECIFICITY; CENTRAL NERVOUS SYSTEM; DEPRESSION; DRUG MECHANISM; DRUG PENETRATION; DRUG TARGETING; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; EXCITOTOXICITY; HEPATITIS C; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; MACROPHAGE; MELANOMA; MENTAL DISEASE; MICROGLIA; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; NERVOUS SYSTEM DISEASES; PATHOLOGY; PHYSIOLOGY;

ANIMALS; HUMANS; KYNURENINE; METABOLIC NETWORKS AND PATHWAYS; NERVOUS SYSTEM DISEASES; TRYPTOPHAN;

EID: 84955442289     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2016.01.011     Document Type: Review

References (171)

1. Adams, S., Teo, C., McDonald, K.L., Zinger, A., Bustamante, S., Lim, C.K., Sundaram, G., Braidy, N., Brew, B.J., Guillemin, G.J., Involvement of the kynurenine pathway in human glioma pathophysiology. PLoS One, 9, 2014, e112945.
2. Aeinehband, S., Brenner, P., Stahl, S., Bhat, M., Fidock, M.D., Khademi, M., Olsson, T., Engberg, G., Jokinen, J., Erhardt, S., Piehl, F., Cerebrospinal fluid kynurenines in multiple sclerosis; relation to disease course and neurocognitive symptoms. Brain Behav. Immun. 51 (2016), 47–55.
3. Aguilera, P., Chanez-Cardenas, M.E., Floriano-Sanchez, E., Barrera, D., Santamaria, A., Sanchez-Gonzalez, D.J., Perez-Severiano, F., Pedraza-Chaverri, J., Jimenez, P.D., Time-related changes in constitutive and inducible nitric oxide synthases in the rat striatum in a model of Huntington's disease. Neurotoxicology 28 (2007), 1200–1207.
4. Alberati-Giani, D., Buchli, R., Malherbe, P., Broger, C., Lang, G., Kohler, C., Lahm, H.W., Cesura, A.M., Isolation and expression of a cDNA clone encoding human kynureninase. Eur. J. Biochem. 239 (1996), 460–468.
5. Alberati-Giani, D., Ricciardi-Castagnoli, P., Kohler, C., Cesura, A.M., Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J. Neurochem. 66 (1996), 996–1004.
6. Alberati-Giani, D., Ricciardi-Castagnoli, P., Kohler, C., Cesura, A.M., Regulation of the kynurenine pathway by IFN-gamma in murine cloned macrophages and microglial cells. Adv. Exp. Med. Biol. 398 (1996), 171–175.
7. Alkondon, M., Pereira, E.F., Yu, P., Arruda, E.Z., Almeida, L.E., Guidetti, P., Fawcett, W.P., Sapko, M.T., Randall, W.R., Schwarcz, R., Tagle, D.A., Albuquerque, E.X., Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus. J. Neurosci. 24 (2004), 4635–4648.
8. Allison, D.J., Ditor, D.S., The common inflammatory etiology of depression and cognitive impairment: a therapeutic target. J. Neuroinflammation, 11, 2014, 151.
9. Amori, L., Wu, H.Q., Marinozzi, M., Pellicciari, R., Guidetti, P., Schwarcz, R., Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience 159 (2009), 196–203.
10. Ball, H.J., Sanchez-Perez, A., Weiser, S., Austin, C.J., Astelbauer, F., Miu, J., McQuillan, J.A., Stocker, R., Jermiin, L.S., Hunt, N.H., Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396 (2007), 203–213.
11. Ball, H.J., Yuasa, H.J., Austin, C.J., Weiser, S., Hunt, N.H., Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int. J. Biochem. Cell Biol. 41 (2009), 467–471.
12. Baran, H., Schwarcz, R., Presence of 3-hydroxyanthranilic acid in rat tissues and evidence for its production from anthranilic acid in the brain. J. Neurochem. 55 (1990), 738–744.
13. Baranyi, A., Meinitzer, A., Breitenecker, R.J., Amouzadeh-Ghadikolai, O., Stauber, R., Rothenhausler, H.B., Quinolinic acid responses during interferon-alpha-induced depressive symptomatology in patients with chronic hepatitis C infection – a novel aspect for depression and inflammatory hypothesis. PLoS One, 10, 2015, e0137022.
14. Baverel, G., Martin, G., Michoudet, C., Glutamine synthesis from aspartate in guinea-pig renal cortex. Biochem. J. 268 (1990), 437–442.
15. Beal, M.F., Matson, W.R., Swartz, K.J., Gamache, P.H., Bird, E.D., Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J. Neurochem. 55 (1990), 1327–1339.
16. Bender, D.A., McCreanor, G.M., The preferred route of kynurenine metabolism in the rat. Biochim. Biophys. Acta 717 (1982), 56–60.
17. Berlinguer-Palmini, R., Masi, A., Narducci, R., Cavone, L., Maratea, D., Cozzi, A., Sili, M., Moroni, F., Mannaioni, G., GPR35 activation reduces Ca2+ transients and contributes to the kynurenic acid-dependent reduction of synaptic activity at CA3-CA1 synapses. PLoS One, 8, 2013, e82180.
18. Birch, P.J., Grossman, C.J., Hayes, A.G., Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor. Eur. J. Pharmacol. 154 (1988), 85–87.
19. Bonaccorso, S., Marino, V., Puzella, A., Pasquini, M., Biondi, M., Artini, M., Almerighi, C., Verkerk, R., Meltzer, H., Maes, M., Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J. Clin. Psychopharmacol. 22 (2002), 86–90.
20. Braidy, N., Grant, R., Adams, S., Brew, B.J., Guillemin, G.J., Mechanism for quinolinic acid cytotoxicity in human astrocytes and neurons. Neurotox. Res. 16 (2009), 77–86.
21. Campbell, B.M., Charych, E., Lee, A.W., Moller, T., Kynurenines in CNS disease: regulation by inflammatory cytokines. Front. Neurosci., 8, 2014, 12.
22. Capuron, L., Neurauter, G., Musselman, D.L., Lawson, D.H., Nemeroff, C.B., Fuchs, D., Miller, A.H., Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol. Psychiatry 54 (2003), 906–914.
23. Cassol, E., Misra, V., Dutta, A., Morgello, S., Gabuzda, D., Cerebrospinal fluid metabolomics reveals altered waste clearance and accelerated aging in HIV patients with neurocognitive impairment. AIDS 28 (2014), 1579–1591.
24. Chang, K.H., Wu, Y.R., Chen, Y.C., Chen, C.M., Plasma inflammatory biomarkers for Huntington's disease patients and mouse model. Brain Behav. Immun. 44 (2015), 121–127.
25. Chess, A.C., Simoni, M.K., Alling, T.E., Bucci, D.J., Elevations of endogenous kynurenic acid produce spatial working memory deficits. Schizophr. Bull. 33 (2007), 797–804.
26. Colin-Gonzalez, A.L., Maldonado, P.D., Santamaria, A., 3-Hydroxykynurenine: an intriguing molecule exerting dual actions in the central nervous system. Neurotoxicology 34 (2013), 189–204.
27. Comai, S., Cavalletto, L., Chemello, L., Bernardinello, E., Ragazzi, E., Costa, C.V., Bertazzo, A., Effects of PEG-interferon alpha plus ribavirin on tryptophan metabolism in patients with chronic hepatitis C. Pharmacol. Res. 63 (2011), 85–92.
28. Connor, T.J., Starr, N., O'Sullivan, J.B., Harkin, A., Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma?. Neurosci. Lett. 441 (2008), 29–34.
29. Croitoru-Lamoury, J., Lamoury, F.M., Caristo, M., Suzuki, K., Walker, D., Takikawa, O., Taylor, R., Brew, B.J., Interferon-gamma regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (IDO). PLoS One, 6, 2011, e14698.
30. Danesch, U., Hashimoto, S., Renkawitz, R., Schutz, G., Transcriptional regulation of the tryptophan oxygenase gene in rat liver by glucocorticoids. J. Biol. Chem. 258 (1983), 4750–4753.
31. de Carvalho, L.P., Bochet, P., Rossier, J., The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem. Int. 28 (1996), 445–452.
32. DiNatale, B.C., Murray, I.A., Schroeder, J.C., Flaveny, C.A., Lahoti, T.S., Laurenzana, E.M., Omiecinski, C.J., Perdew, G.H., Kynurenic acid is a potent endogenous aryl hydrocarbon receptor ligand that synergistically induces interleukin-6 in the presence of inflammatory signaling. Toxicol. Sci. 115 (2010), 89–97.
33. Dobos, N., de Vries, E.F., Kema, I.P., Patas, K., Prins, M., Nijholt, I.M., Dierckx, R.A., Korf, J., den Boer, J.A., Luiten, P.G., Eisel, U.L., The role of indoleamine 2,3-dioxygenase in a mouse model of neuroinflammation-induced depression. J. Alzheimers Dis. 28 (2012), 905–915.
34. Eastman, C.L., Guilarte, T.R., Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line. Brain Res. 495 (1989), 225–231.
35. Eastman, C.L., Guilarte, T.R., The role of hydrogen peroxide in the in vitro cytotoxicity of 3-hydroxykynurenine. Neurochem. Res. 15 (1990), 1101–1107.
36. Erhardt, S., Blennow, K., Nordin, C., Skogh, E., Lindstrom, L.H., Engberg, G., Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia. Neurosci. Lett. 313 (2001), 96–98.
37. Espey, M.G., Chernyshev, O.N., Reinhard, J.F. Jr., Namboodiri, M.A., Colton, C.A., Activated human microglia produce the excitotoxin quinolinic acid. Neuroreport 8 (1997), 431–434.
38. Faurbye, A., Pind, K., Investigations on the tryptophane metabolism (via kynurenine) in schizophrenic patients. Acta Psychiatr. Scand. 40 (1964), 244–248.
39. Foster, A.C., Vezzani, A., French, E.D., Schwarcz, R., Kynurenic acid blocks neurotoxicity and seizures induced in rats by the related brain metabolite quinolinic acid. Neurosci. Lett. 48 (1984), 273–278.
40. Foster, A.C., White, R.J., Schwarcz, R., Synthesis of quinolinic acid by 3-hydroxyanthranilic acid oxygenase in rat brain tissue in vitro. J. Neurochem. 47 (1986), 23–30.
41. Fujigaki, H., Saito, K., Fujigaki, S., Takemura, M., Sudo, K., Ishiguro, H., Seishima, M., The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J. Biochem. 139 (2006), 655–662.
42. Fujigaki, S., Saito, K., Sekikawa, K., Tone, S., Takikawa, O., Fujii, H., Wada, H., Noma, A., Seishima, M., Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur. J. Immunol. 31 (2001), 2313–2318.
43. Fujigaki, S., Saito, K., Takemura, M., Maekawa, N., Yamada, Y., Wada, H., Seishima, M., L-tryptophan-L-kynurenine pathway metabolism accelerated by Toxoplasma gondii infection is abolished in gamma interferon-gene-deficient mice: cross-regulation between inducible nitric oxide synthase and indoleamine-2,3-dioxygenase. Infect. Immun. 70 (2002), 779–786.
44. Fukui, S., Schwarcz, R., Rapoport, S.I., Takada, Y., Smith, Q.R., Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J. Neurochem. 56 (1991), 2007–2017.
45. Fukunaga, M., Yamamoto, Y., Kawasoe, M., Arioka, Y., Murakami, Y., Hoshi, M., Saito, K., Studies on tissue and cellular distribution of indoleamine 2,3-dioxygenase 2: the absence of IDO1 upregulates IDO2 expression in the epididymis. J. Histochem. Cytochem. 60 (2012), 854–860.
46. Gal, E.M., Sherman, A.D., L-kynurenine: its synthesis and possible regulatory function in brain. Neurochem. Res. 5 (1980), 223–239.
47. Giorgini, F., Huang, S.Y., Sathyasaikumar, K.V., Notarangelo, F.M., Thomas, M.A., Tararina, M., Wu, H.Q., Schwarcz, R., Muchowski, P.J., Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain. J. Biol. Chem. 288 (2013), 36554–36566.
48. Goda, K., Hisaoka, M., Ueda, T., Photoinduced electron transfer reaction from N-formyl-L-kynurenine and L-kynurenine to cytochrome C. Biochem. Int. 15 (1987), 635–643.
49. Greilberger, J., Fuchs, D., Leblhuber, F., Greilberger, M., Wintersteiger, R., Tafeit, E., Carbonyl proteins as a clinical marker in Alzheimer's disease and its relation to tryptophan degradation and immune activation. Clin. Lab. 56 (2010), 441–448.
50. Guidetti, P., Amori, L., Sapko, M.T., Okuno, E., Schwarcz, R., Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J. Neurochem. 102 (2007), 103–111.
51. Guillemin, G.J., Quinolinic acid, the inescapable neurotoxin. FEBS J. 279 (2012), 1356–1365.
52. Guillemin, G.J., Kerr, S.J., Smythe, G.A., Armati, P.J., Brew, B.J., Kynurenine pathway metabolism in human astrocytes. Adv. Exp. Med. Biol. 467 (1999), 125–131.
53. Guillemin, G.J., Kerr, S.J., Smythe, G.A., Smith, D.G., Kapoor, V., Armati, P.J., Croitoru, J., Brew, B.J., Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 78 (2001), 842–853.
54. Guillemin, G.J., Williams, K.R., Smith, D.G., Smythe, G.A., Croitoru-Lamoury, J., Brew, B.J., Quinolinic acid in the pathogenesis of Alzheimer's disease. Adv. Exp. Med. Biol. 527 (2003), 167–176.
55. Gulaj, E., Pawlak, K., Bien, B., Pawlak, D., Kynurenine and its metabolites in Alzheimer's disease patients. Adv. Med. Sci. 55 (2010), 204–211.
56. Haber, R., Bessette, D., Hulihan-Giblin, B., Durcan, M.J., Goldman, D., Identification of tryptophan 2,3-dioxygenase RNA in rodent brain. J. Neurochem. 60 (1993), 1159–1162.
57. Han, Q., Cai, T., Tagle, D.A., Li, J., Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell. Mol. Life Sci. 67 (2010), 353–368.
58. Hardeland, R., Zsizsik, B.K., Poeggeler, B., Fuhrberg, B., Holst, S., Coto-Montes, A., Indole-3-pyruvic and -propionic acids, kynurenic acid, and related metabolites as luminophores and free-radical scavengers. Adv. Exp. Med. Biol. 467 (1999), 389–395.
59. Hartai, Z., Juhasz, A., Rimanoczy, A., Janaky, T., Donko, T., Dux, L., Penke, B., Toth, G.K., Janka, Z., Kalman, J., Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease. Neurochem. Int. 50 (2007), 308–313.
60. Heyes, M.P., Achim, C.L., Wiley, C.A., Major, E.O., Saito, K., Markey, S.P., Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 320:Pt 2 (1996), 595–597.
61. Heyes, M.P., Brew, B.J., Martin, A., Price, R.W., Salazar, A.M., Sidtis, J.J., Yergey, J.A., Mouradian, M.M., Sadler, A.E., Keilp, J., et al. Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann. Neurol. 29 (1991), 202–209.
62. Heyes, M.P., Chen, C.Y., Major, E.O., Saito, K., Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types. Biochem. J. 326:Pt 2 (1997), 351–356.
63. Heyes, M.P., Morrison, P.F., Quantification of local de novo synthesis versus blood contributions to quinolinic acid concentrations in brain and systemic tissues. J. Neurochem. 68 (1997), 280–288.
64. Heyes, M.P., Saito, K., Chen, C.Y., Proescholdt, M.G., Nowak, T.S. Jr., Li, J., Beagles, K.E., Proescholdt, M.A., Zito, M.A., Kawai, K., Markey, S.P., Species heterogeneity between gerbils and rats: quinolinate production by microglia and astrocytes and accumulations in response to ischemic brain injury and systemic immune activation. J. Neurochem. 69 (1997), 1519–1529.
65. Heyes, M.P., Saito, K., Crowley, J.S., Davis, L.E., Demitrack, M.A., Der, M., Dilling, L.A., Elia, J., Kruesi, M.J., Lackner, A., et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115:Pt 5 (1992), 1249–1273.
66. Heyes, M.P., Saito, K., Lackner, A., Wiley, C.A., Achim, C.L., Markey, S.P., Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques. FASEB J. 12 (1998), 881–896.
67. Heyes, M.P., Saito, K., Markey, S.P., Human macrophages convert L-tryptophan into the neurotoxin quinolinic acid. Biochem. J. 283:Pt 3 (1992), 633–635.
68. Hilmas, C., Pereira, E.F., Alkondon, M., Rassoulpour, A., Schwarcz, R., Albuquerque, E.X., The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications. J. Neurosci. 21 (2001), 7463–7473.
69. Hoshi, M., Saito, K., Murakami, Y., Taguchi, A., Fujigaki, H., Tanaka, R., Takemura, M., Ito, H., Hara, A., Seishima, M., Marked increases in hippocampal neuron indoleamine 2, 3-dioxygenase via IFN-gamma-independent pathway following transient global ischemia in mouse. Neurosci. Res. 63 (2009), 194–198.
70. Huengsberg, M., Winer, J.B., Gompels, M., Round, R., Ross, J., Shahmanesh, M., Serum kynurenine-to-tryptophan ratio increases with progressive disease in HIV-infected patients. Clin. Chem. 44 (1998), 858–862.
71. Jamwal, S., Singh, S., Kaur, N., Kumar, P., Protective effect of spermidine against excitotoxic neuronal death induced by quinolinic acid in rats: possible neurotransmitters and neuroinflammatory mechanism. Neurotox. Res. 28 (2015), 171–184.
72. Kegel, M.E., Bhat, M., Skogh, E., Samuelsson, M., Lundberg, K., Dahl, M.L., Sellgren, C., Schwieler, L., Engberg, G., Schuppe-Koistinen, I., Erhardt, S., Imbalanced kynurenine pathway in schizophrenia. Int. J. Tryptophan Res. 7 (2014), 15–22.
73. Kessler, M., Terramani, T., Lynch, G., Baudry, M., A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J. Neurochem. 52 (1989), 1319–1328.
74. Klivenyi, P., Toldi, J., Vecsei, L., Kynurenines in neurodegenerative disorders: therapeutic consideration. Adv. Exp. Med. Biol. 541 (2004), 169–183.
75. Koshy Cherian, A., Gritton, H., Johnson, D.E., Young, D., Kozak, R., Sarter, M., A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats. Neuropharmacology 82 (2014), 41–48.
76. Kozak, R., Campbell, B.M., Strick, C.A., Horner, W., Hoffmann, W.E., Kiss, T., Chapin, D.S., McGinnis, D., Abbott, A.L., Roberts, B.M., Fonseca, K., Guanowsky, V., Young, D.A., Seymour, P.A., Dounay, A., Hajos, M., Williams, G.V., Castner, S.A., Reduction of brain kynurenic acid improves cognitive function. J. Neurosci. 34 (2014), 10592–10602.
77. Lapin, I.P., Kynurenines as probable participants of depression. Pharmakopsychiatr. Neuropsychopharmakol. 6 (1973), 273–279.
78. Lavebratt, C., Olsson, S., Backlund, L., Frisen, L., Sellgren, C., Priebe, L., Nikamo, P., Traskman-Bendz, L., Cichon, S., Vawter, M.P., Osby, U., Engberg, G., Landen, M., Erhardt, S., Schalling, M., The KMO allele encoding Arg452 is associated with psychotic features in bipolar disorder type 1, and with increased CSF KYNA level and reduced KMO expression. Mol. Psychiatry 19 (2014), 334–341.
79. Lawson, M.A., Parrott, J.M., McCusker, R.H., Dantzer, R., Kelley, K.W., O'Connor, J.C., Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors. J. Neuroinflammation, 10, 2013, 87.
80. Lee, M.C., Ting, K.K., Adams, S., Brew, B.J., Chung, R., Guillemin, G.J., Characterisation of the expression of NMDA receptors in human astrocytes. PLoS One, 5, 2010, e14123.
81. Linderholm, K.R., Alm, M.T., Larsson, M.K., Olsson, S.K., Goiny, M., Hajos, M., Erhardt, S., Engberg, G., Inhibition of kynurenine aminotransferase II reduces activity of midbrain dopamine neurons. Neuropharmacology 102 (2015), 42–47.
82. Linderholm, K.R., Skogh, E., Olsson, S.K., Dahl, M.L., Holtze, M., Engberg, G., Samuelsson, M., Erhardt, S., Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr. Bull. 38 (2012), 426–432.
83. Liu, J.J., Raynal, S., Bailbe, D., Gausseres, B., Carbonne, C., Autier, V., Movassat, J., Kergoat, M., Portha, B., Expression of the kynurenine pathway enzymes in the pancreatic islet cells. Activation by cytokines and glucolipotoxicity. Biochim. Biophys. Acta 1852 (2015), 980–991.
84. Lob, S., Konigsrainer, A., Zieker, D., Brucher, B.L., Rammensee, H.G., Opelz, G., Terness, P., IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol. Immunother. 58 (2009), 153–157.
85. Lugo-Huitron, R., Blanco-Ayala, T., Ugalde-Muniz, P., Carrillo-Mora, P., Pedraza-Chaverri, J., Silva-Adaya, D., Maldonado, P.D., Torres, I., Pinzon, E., Ortiz-Islas, E., Lopez, T., Garcia, E., Pineda, B., Torres-Ramos, M., Santamaria, A., La Cruz, V.P., On the antioxidant properties of kynurenic acid: free radical scavenging activity and inhibition of oxidative stress. Neurotoxicol. Teratol. 33 (2011), 538–547.
86. Lugo-Huitron, R., Ugalde Muniz, P., Pineda, B., Pedraza-Chaverri, J., Rios, C., Perez-de la Cruz, V., Quinolinic acid: an endogenous neurotoxin with multiple targets. Oxid. Med. Cell. Longev., 2013, 2013, 104024.
87. Malaczewska, J., Siwicki, A.K., Wojcik, R.M., Kaczorek, E., Turski, W.A., Effect of oral administration of kynurenic acid on the activity of the peripheral blood leukocytes in mice. Cent. Eur. J. Immunol. 39 (2014), 6–13.
88. Mancuso, R., Hernis, A., Agostini, S., Rovaris, M., Caputo, D., Fuchs, D., Clerici, M., Indoleamine 2,3 dioxygenase (IDO) expression and activity in relapsing-remitting multiple sclerosis. PLoS One, 10, 2015, e0130715.
89. Meier, T.B., Drevets, W.C., Wurfel, B.E., Ford, B.N., Morris, H.M., Victor, T.A., Bodurka, J., Teague, T.K., Dantzer, R., Savitz, J., Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder. Brain Behav. Immun., 2015, 10.1016/j.bbi.2015.11.003.
90. Metz, R., Duhadaway, J.B., Kamasani, U., Laury-Kleintop, L., Muller, A.J., Prendergast, G.C., Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 67 (2007), 7082–7087.
91. Morita, T., Saito, K., Takemura, M., Maekawa, N., Fujigaki, S., Fujii, H., Wada, H., Takeuchi, S., Noma, A., Seishima, M., 3-Hydroxyanthranilic acid, an L-tryptophan metabolite, induces apoptosis in monocyte-derived cells stimulated by interferon-gamma. Ann. Clin. Biochem. 38 (2001), 242–251.
92. Moroni, F., Cozzi, A., Sili, M., Mannaioni, G., Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J. Neural Transm. 119 (2012), 133–139.
93. Murakami, Y., Saito, K., Species and cell types difference in tryptophan metabolism. Int. J. Tryptophan Res. 6 (2013), 47–54.
94. Murray, M.F., Insights into therapy: tryptophan oxidation and HIV infection. Sci. Transl. Med., 2, 2010, 32ps23.
95. Myint, A.M., Kim, Y.K., Verkerk, R., Scharpe, S., Steinbusch, H., Leonard, B., Kynurenine pathway in major depression: evidence of impaired neuroprotection. J. Affect Disord. 98 (2007), 143–151.
96. Nemeth, H., Toldi, J., Vecsei, L., Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies. J. Neural Transm. Suppl., 2006, 285–304.
97. Nilsson, L.K., Linderholm, K.R., Engberg, G., Paulson, L., Blennow, K., Lindstrom, L.H., Nordin, C., Karanti, A., Persson, P., Erhardt, S., Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr. Res. 80 (2005), 315–322.
98. O'Connor, J.C., Andre, C., Wang, Y., Lawson, M.A., Szegedi, S.S., Lestage, J., Castanon, N., Kelley, K.W., Dantzer, R., Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J. Neurosci. 29 (2009), 4200–4209.
99. O'Connor, J.C., Lawson, M.A., Andre, C., Moreau, M., Lestage, J., Castanon, N., Kelley, K.W., Dantzer, R., Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 14 (2009), 511–522.
100. Okuda, S., Nishiyama, N., Saito, H., Katsuki, H., Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine. Proc. Natl. Acad. Sci. U. S. A. 93 (1996), 12553–12558.
101. Okuno, E., Nakamura, M., Schwarcz, R., Two kynurenine aminotransferases in human brain. Brain Res. 542 (1991), 307–312.
102. Olney, J.W., Labruyere, J., Wang, G., Wozniak, D.F., Price, M.T., Sesma, M.A., NMDA antagonist neurotoxicity: mechanism and prevention. Science 254 (1991), 1515–1518.
103. Opitz, C.A., Litzenburger, U.M., Sahm, F., Ott, M., Tritschler, I., Trump, S., Schumacher, T., Jestaedt, L., Schrenk, D., Weller, M., Jugold, M., Guillemin, G.J., Miller, C.L., Lutz, C., Radlwimmer, B., Lehmann, I., von Deimling, A., Wick, W., Platten, M., An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478 (2011), 197–203.
104. Paguirigan, A.M., Byrne, G.I., Becht, S., Carlin, J.M., Cytokine-mediated indoleamine 2,3-dioxygenase induction in response to Chlamydia infection in human macrophage cultures. Infect. Immun. 62 (1994), 1131–1136.
105. Parrott, J.M., O'Connor, J.C., Kynurenine 3-monooxygenase: an influential mediator of neuropathology. Front. Psychiatry, 6, 2015, 116.
106. Pavese, N., Gerhard, A., Tai, Y.F., Ho, A.K., Turkheimer, F., Barker, R.A., Brooks, D.J., Piccini, P., Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology 66 (2006), 1638–1643.
107. Peyrot, F., Ducrocq, C., Potential role of tryptophan derivatives in stress responses characterized by the generation of reactive oxygen and nitrogen species. J. Pineal Res. 45 (2008), 235–246.
108. Pfefferkorn, E.R., Rebhun, S., Eckel, M., Characterization of an indoleamine 2,3-dioxygenase induced by gamma-interferon in cultured human fibroblasts. J. Interferon Res. 6 (1986), 267–279.
109. Phillips, R.S., Structure, mechanism, and substrate specificity of kynureninase. Biochim. Biophys. Acta 1814 (2011), 1481–1488.
110. Pierozan, P., Zamoner, A., Soska, A.K., Silvestrin, R.B., Loureiro, S.O., Heimfarth, L., Mello e Souza, T., Wajner, M., Pessoa-Pureur, R., Acute intrastriatal administration of quinolinic acid provokes hyperphosphorylation of cytoskeletal intermediate filament proteins in astrocytes and neurons of rats. Exp. Neurol. 224 (2010), 188–196.
111. Pittaluga, A., Pattarini, R., Feligioni, M., Raiteri, M., N-methyl-D-aspartate receptors mediating hippocampal noradrenaline and striatal dopamine release display differential sensitivity to quinolinic acid, the HIV-1 envelope protein gp120, external pH and protein kinase C inhibition. J. Neurochem. 76 (2001), 139–148.
112. Rahman, A., Ting, K., Cullen, K.M., Braidy, N., Brew, B.J., Guillemin, G.J., The excitotoxin quinolinic acid induces tau phosphorylation in human neurons. PLoS One, 4, 2009, e6344.
113. Raison, C.L., Dantzer, R., Kelley, K.W., Lawson, M.A., Woolwine, B.J., Vogt, G., Spivey, J.R., Saito, K., Miller, A.H., CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 15 (2010), 393–403.
114. Rassoulpour, A., Wu, H.Q., Ferre, S., Schwarcz, R., Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J. Neurochem. 93 (2005), 762–765.
115. Reyes-Ocampo, J., Ramirez-Ortega, D., Vazquez Cervantes, G.I., Pineda, B., Montes de Oca Balderas, P., Gonzalez-Esquivel, D., Sanchez-Chapul, L., Lugo-Huitron, R., Silva-Adaya, D., Rios, C., Jimenez-Anguiano, A., Perez-de la Cruz, V., Mitochondrial dysfunction related to cell damage induced by 3-hydroxykynurenine and 3-hydroxyanthranilic acid: non-dependent-effect of early reactive oxygen species production. Neurotoxicology 50 (2015), 81–91.
116. Reyes Ocampo, J., Lugo Huitron, R., Gonzalez-Esquivel, D., Ugalde-Muniz, P., Jimenez-Anguiano, A., Pineda, B., Pedraza-Chaverri, J., Rios, C., Perez de la Cruz, V., Kynurenines with neuroactive and redox properties: relevance to aging and brain diseases. Oxid. Med. Cell. Longev., 2014, 2014, 646909.
117. Reynolds, I.J., Harris, K.M., Miller, R.J., NMDA receptor antagonists that bind to the strychnine-insensitive glycine site and inhibit NMDA-induced Ca2+ fluxes and [3H]GABA release. Eur. J. Pharmacol. 172 (1989), 9–17.
118. Rios, C., Santamaria, A., Quinolinic acid is a potent lipid peroxidant in rat brain homogenates. Neurochem. Res. 16 (1991), 1139–1143.
119. Saito, K., Heyes, M.P., Kynurenine pathway enzymes in brain. Properties of enzymes and regulation of quinolinic acid synthesis. Adv. Exp. Med. Biol. 398 (1996), 485–492.
120. Saito, K., Lackner, A., Markey, S.P., Heyes, M.P., Cerebral cortex and lung indoleamine-2,3-dioxygenase activity is increased in type-D retrovirus infected macaques. Brain Res. 540 (1991), 353–356.
121. Saito, K., Markey, S.P., Heyes, M.P., Chronic effects of gamma-interferon on quinolinic acid and indoleamine-2,3-dioxygenase in brain of C57BL6 mice. Brain Res. 546 (1991), 151–154.
122. Saito, K., Markey, S.P., Heyes, M.P., Effects of immune activation on quinolinic acid and neuroactive kynurenines in the mouse. Neuroscience 51 (1992), 25–39.
123. Saito, K., Nowak, T.S. Jr., Markey, S.P., Heyes, M.P., Mechanism of delayed increases in kynurenine pathway metabolism in damaged brain regions following transient cerebral ischemia. J. Neurochem. 60 (1993), 180–192.
124. Saito, K., Nowak, T.S. Jr., Suyama, K., Quearry, B.J., Saito, M., Crowley, J.S., Markey, S.P., Heyes, M.P., Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation. J. Neurochem. 61 (1993), 2061–2070.
125. Saito, K., Quearry, B.J., Saito, M., Nowak, T.S. Jr., Markey, S.P., Heyes, M.P., Kynurenine 3-hydroxylase in brain: species activity differences and effect of gerbil cerebral ischemia. Arch. Biochem. Biophys. 307 (1993), 104–109.
126. Salter, M., Pogson, C.I., The role of tryptophan 2,3-dioxygenase in the hormonal control of tryptophan metabolism in isolated rat liver cells. Effects of glucocorticoids and experimental diabetes. Biochem. J. 229 (1985), 499–504.
127. Santamaria, A., Galvan-Arzate, S., Lisy, V., Ali, S.F., Duhart, H.M., Osorio-Rico, L., Rios, C., St'astny, F., Quinolinic acid induces oxidative stress in rat brain synaptosomes. Neuroreport 12 (2001), 871–874.
128. Santamaria, A., Jimenez-Capdeville, M.E., Camacho, A., Rodriguez-Martinez, E., Flores, A., Galvan-Arzate, S., In vivo hydroxyl radical formation after quinolinic acid infusion into rat corpus striatum. Neuroreport 12 (2001), 2693–2696.
129. Sapp, E., Kegel, K.B., Aronin, N., Hashikawa, T., Uchiyama, Y., Tohyama, K., Bhide, P.G., Vonsattel, J.P., DiFiglia, M., Early and progressive accumulation of reactive microglia in the Huntington disease brain. J. Neuropathol. Exp. Neurol. 60 (2001), 161–172.
130. Sathyasaikumar, K.V., Stachowski, E.K., Wonodi, I., Roberts, R.C., Rassoulpour, A., McMahon, R.P., Schwarcz, R., Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr. Bull. 37 (2011), 1147–1156.
131. Savitz, J., Dantzer, R., Meier, T.B., Wurfel, B.E., Victor, T.A., McIntosh, S.A., Ford, B.N., Morris, H.M., Bodurka, J., Teague, T.K., Drevets, W.C., Activation of the kynurenine pathway is associated with striatal volume in major depressive disorder. Psychoneuroendocrinology 62 (2015), 54–58.
132. Savitz, J., Dantzer, R., Wurfel, B.E., Victor, T.A., Ford, B.N., Bodurka, J., Bellgowan, P.S., Teague, T.K., Drevets, W.C., Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. Psychoneuroendocrinology 52 (2015), 200–211.
133. Savitz, J., Drevets, W.C., Smith, C.M., Victor, T.A., Wurfel, B.E., Bellgowan, P.S., Bodurka, J., Teague, T.K., Dantzer, R., Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. Neuropsychopharmacology 40 (2015), 463–471.
134. Savitz, J., Drevets, W.C., Wurfel, B.E., Ford, B.N., Bellgowan, P.S., Victor, T.A., Bodurka, J., Teague, T.K., Dantzer, R., Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain Behav. Immun. 46 (2015), 55–59.
135. Schroecksnadel, K., Zangerle, R., Bellmann-Weiler, R., Garimorth, K., Weiss, G., Fuchs, D., Indoleamine-2, 3-dioxygenase and other interferon-gamma-mediated pathways in patients with human immunodeficiency virus infection. Curr. Drug Metab. 8 (2007), 225–236.
136. Schwarcz, R., Bruno, J.P., Muchowski, P.J., Wu, H.Q., Kynurenines in the mammalian brain: when physiology meets pathology. Nat. Rev. Neurosci. 13 (2012), 465–477.
137. Schwarcz, R., Kohler, C., Differential vulnerability of central neurons of the rat to quinolinic acid. Neurosci. Lett. 38 (1983), 85–90.
138. Schwarcz, R., Rassoulpour, A., Wu, H.Q., Medoff, D., Tamminga, C.A., Roberts, R.C., Increased cortical kynurenate content in schizophrenia. Biol. Psychiatry 50 (2001), 521–530.
139. Schwarcz, R., Whetsell, W.O. Jr., Mangano, R.M., Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain. Science 219 (1983), 316–318.
140. Schwieler, L., Larsson, M.K., Skogh, E., Kegel, M.E., Orhan, F., Abdelmoaty, S., Finn, A., Bhat, M., Samuelsson, M., Lundberg, K., Dahl, M.L., Sellgren, C., Schuppe-Koistinen, I., Svensson, C., Erhardt, S., Engberg, G., Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia–significance for activation of the kynurenine pathway. J. Psychiatry Neurosci. 40 (2015), 126–133.
141. Shepard, P.D., Joy, B., Clerkin, L., Schwarcz, R., Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology 28 (2003), 1454–1462.
142. Shimizu, T., Nomiyama, S., Hirata, F., Hayaishi, O., Indoleamine 2,3-dioxygenase. Purification and some properties. J. Biol. Chem. 253 (1978), 4700–4706.
143. Song, H., Park, H., Kim, Y.S., Kim, K.D., Lee, H.K., Cho, D.H., Yang, J.W., Hur, D.Y., L-kynurenine-induced apoptosis in human NK cells is mediated by reactive oxygen species. Int. Immunopharmacol. 11 (2011), 932–938.
144. Speciale, C., Hares, K., Schwarcz, R., Brookes, N., High-affinity uptake of L-kynurenine by a Na+-independent transporter of neutral amino acids in astrocytes. J. Neurosci. 9 (1989), 2066–2072.
145. Speciale, C., Schwarcz, R., Uptake of kynurenine into rat brain slices. J. Neurochem. 54 (1990), 156–163.
146. Stone, T.W., Kynurenic acid blocks nicotinic synaptic transmission to hippocampal interneurons in young rats. Eur. J. Neurosci. 25 (2007), 2656–2665.
147. Stone, T.W., Darlington, L.G., Endogenous kynurenines as targets for drug discovery and development. Nat. Rev. Drug Discov. 1 (2002), 609–620.
148. Stone, T.W., Perkins, M.N., Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS. Eur. J. Pharmacol. 72 (1981), 411–412.
149. Stoy, N., Mackay, G.M., Forrest, C.M., Christofides, J., Egerton, M., Stone, T.W., Darlington, L.G., Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J. Neurochem. 93 (2005), 611–623.
150. Takikawa, O., Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated L-tryptophan metabolism. Biochem. Biophys. Res. Commun. 338 (2005), 12–19.
151. Takikawa, O., Kuroiwa, T., Yamazaki, F., Kido, R., Mechanism of interferon-gamma action. Characterization of indoleamine 2,3-dioxygenase in cultured human cells induced by interferon-gamma and evaluation of the enzyme-mediated tryptophan degradation in its anticellular activity. J. Biol. Chem. 263 (1988), 2041–2048.
152. Tavares, R.G., Tasca, C.I., Santos, C.E., Alves, L.B., Porciuncula, L.O., Emanuelli, T., Souza, D.O., Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem. Int. 40 (2002), 621–627.
153. Tavares, R.G., Tasca, C.I., Santos, C.E., Wajner, M., Souza, D.O., Dutra-Filho, C.S., Quinolinic acid inhibits glutamate uptake into synaptic vesicles from rat brain. Neuroreport 11 (2000), 249–253.
154. Taylor, M.W., Feng, G.S., Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5 (1991), 2516–2522.
155. Ting, K.K., Brew, B.J., Guillemin, G.J., Effect of quinolinic acid on human astrocytes morphology and functions: implications in Alzheimer's disease. J. Neuroinflammation, 6, 2009, 36.
156. Toma, S., Nakamura, M., Tone, S., Okuno, E., Kido, R., Breton, J., Avanzi, N., Cozzi, L., Speciale, C., Mostardini, M., Gatti, S., Benatti, L., Cloning and recombinant expression of rat and human kynureninase. FEBS Lett. 408 (1997), 5–10.
157. Tsopmo, A., Diehl-Jones, B.W., Aluko, R.E., Kitts, D.D., Elisia, I., Friel, J.K., Tryptophan released from mother's milk has antioxidant properties. Pediatr. Res. 66 (2009), 614–618.
158. Wang, J., Simonavicius, N., Wu, X., Swaminath, G., Reagan, J., Tian, H., Ling, L., Kynurenic acid as a ligand for orphan G protein-coupled receptor GPR35. J. Biol. Chem. 281 (2006), 22021–22028.
159. Wichers, M.C., Koek, G.H., Robaeys, G., Verkerk, R., Scharpe, S., Maes, M., IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol. Psychiatry 10 (2005), 538–544.
160. Wichers, M.C., Maes, M., The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J. Psychiatry Neurosci. 29 (2004), 11–17.
161. Widner, B., Leblhuber, F., Fuchs, D., Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J. Neural Transm. Vienna 109 (2002), 181–189.
162. Widner, B., Leblhuber, F., Walli, J., Tilz, G.P., Demel, U., Fuchs, D., Degradation of tryptophan in neurodegenerative disorders. Adv. Exp. Med. Biol. 467 (1999), 133–138.
163. Wissmann, P., Geisler, S., Leblhuber, F., Fuchs, D., Immune activation in patients with Alzheimer's disease is associated with high serum phenylalanine concentrations. J. Neurol. Sci. 329 (2013), 29–33.
164. Witkiewicz, A.K., Costantino, C.L., Metz, R., Muller, A.J., Prendergast, G.C., Yeo, C.J., Brody, J.R., Genotyping and expression analysis of IDO2 in human pancreatic cancer: a novel, active target. J. Am. Coll. Surg. 208 (2009), 787–789 781–787; discussion.
165. Wonodi, I., Stine, O.C., Sathyasaikumar, K.V., Roberts, R.C., Mitchell, B.D., Hong, L.E., Kajii, Y., Thaker, G.K., Schwarcz, R., Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch. Gen. Psychiatry 68 (2011), 665–674.
166. Yamazaki, F., Kuroiwa, T., Takikawa, O., Kido, R., Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. Biochem. J. 230 (1985), 635–638.
167. Yu, P., Di Prospero, N.A., Sapko, M.T., Cai, T., Chen, A., Melendez-Ferro, M., Du, F., Whetsell, W.O. Jr., Guidetti, P., Schwarcz, R., Tagle, D.A., Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice. Mol. Cell. Biol. 24 (2004), 6919–6930.
168. Yu, P., Li, Z., Zhang, L., Tagle, D.A., Cai, T., Characterization of kynurenine aminotransferase III, a novel member of a phylogenetically conserved KAT family. Gene 365 (2006), 111–118.
169. Yuasa, H.J., Takubo, M., Takahashi, A., Hasegawa, T., Noma, H., Suzuki, T., Evolution of vertebrate indoleamine 2,3-dioxygenases. J. Mol. Evol. 65 (2007), 705–714.
170. Zunszain, P.A., Anacker, C., Cattaneo, A., Choudhury, S., Musaelyan, K., Myint, A.M., Thuret, S., Price, J., Pariante, C.M., Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology 37 (2012), 939–949.
171. Zwilling, D., Huang, S.Y., Sathyasaikumar, K.V., Notarangelo, F.M., Guidetti, P., Wu, H.Q., Lee, J., Truong, J., Andrews-Zwilling, Y., Hsieh, E.W., Louie, J.Y., Wu, T., Scearce-Levie, K., Patrick, C., Adame, A., Giorgini, F., Moussaoui, S., Laue, G., Rassoulpour, A., Flik, G., Huang, Y., Muchowski, J.M., Masliah, E., Schwarcz, R., Muchowski, P.J., Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell 145 (2011), 863–874.